- Conditions
- Chronic Periodontitis
- Interventions
- Oral Antibiotic and Oral Rinse, Standard Treatment
- Drug · Procedure
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2833–2856
of 5,940
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cardiomyopathy, Hypertrophic
- Interventions
- LCZ696, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 5
- States / cities
- Stanford, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
- Conditions
- Mouth, Edentulous
- Interventions
- Ankylos dental endosseous implants-Sub-crestal, Ankylos dental endosseous implants-Epi-crestal
- Device
- Lead sponsor
- Dentsply International
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Solid Tumors, CNS Tumors
- Interventions
- Entrectinib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 0 Years to 18 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 15
- States / cities
- La Jolla, California • San Francisco, California • Aurora, Colorado + 12 more
- Conditions
- Behcet Syndrome
- Interventions
- Tocilizumab
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Dementia, Delirium
- Interventions
- Quetiapine 25 mg gel applied topically, Quetiapine 25 mg tablet by mouth, Quetiapine 25 mg rectal suppository
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
- Interventions
- Pf-05175157, placebo, midazolam
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- South Miami, Florida
- Conditions
- Dysplasia, Lip and Oral Cavity Carcinoma, Oral Disorder, Premalignant Lesion
- Interventions
- Biopsy, Fluorescence Imaging, High-Resolution Microendoscopy, Proflavine Hemisulfate
- Procedure · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Alveolar Bone Loss
- Interventions
- Tissue Repair Cells (TRC), Control
- Biological · Device
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 20 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Peanut Hypersensitivity
- Interventions
- Peanut Oral Immunotherapy - Liquid Extract, Placebo for Peanut Oral Immunotherapy - Liquid Extract form, Peanut Oral Immunotherapy - Peanut Flour, Placebo for Peanut Oral Immunotherapy - Peanut Flour
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Months to 48 Months
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Stanford, California • Baltimore, Maryland + 2 more
- Conditions
- Opioid Dependence, Methadone Withdrawal Syndrome
- Interventions
- Lofexidine HCl
- Drug
- Lead sponsor
- USWM, LLC (dba US WorldMeds)
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Retinitis Pigmentosa
- Interventions
- Valproic Acid, Placebo
- Drug
- Lead sponsor
- Foundation Fighting Blindness
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 6
- States / cities
- Miami, Florida • Ann Arbor, Michigan • Portland, Oregon + 3 more
- Conditions
- AML and High Risk MDS
- Interventions
- LGH447, LGH447 + midostaurin
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
- Interventions
- dasatinib, pharmacological study, laboratory biomarker analysis
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Anemia, Sickle Cell
- Interventions
- HBI-002
- Drug
- Lead sponsor
- Hillhurst Biopharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Myelodysplastic Syndrome
- Interventions
- ON 01910.Na
- Drug
- Lead sponsor
- Traws Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 2
- States / cities
- Tampa, Florida • New York, New York
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- tanespimycin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2005
- U.S. locations
- 2
- States / cities
- Los Angeles, California • New York, New York
- Conditions
- Neoplasms by Site, Lymphoma, Non-hodgkin, Hodgkin Disease, Multiple Myeloma, Leukemia, Lymphocytic, Chronic
- Interventions
- PCI-24781
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 4
- States / cities
- Greenbrae, California • Chicago, Illinois • Nashville, Tennessee + 1 more
- Conditions
- Meningococcal Infections
- Interventions
- MenACWY-CRM + MMRV, MMRV, MenACWY-CRM
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 7 Months to 1 Year
- Enrollment
- 1,630 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 90
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Greenville, Alabama + 69 more
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma, Unresectable Solid Neoplasm
- Interventions
- Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Veliparib
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 5
- States / cities
- New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 2 more
- Conditions
- Gingival Recession
- Interventions
- Puros® Dermis versus Alloderm®
- Device
- Lead sponsor
- Zimmer Biomet
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Ann Arbor, Michigan • Newark, New Jersey + 1 more
- Conditions
- Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Tongue Cancer
- Interventions
- everolimus, erlotinib hydrochloride, biopsy, laboratory biomarker analysis, immunohistochemistry staining method, polyacrylamide gel electrophoresis, pharmacological study, external beam radiation therapy, microarray analysis
- Drug · Procedure · Other + 2 more
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Oral Dystonia, Tardive Dystonia
- Interventions
- Low Dose - AbobotulinumtoxinA
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Orthopoxviral Disease
- Interventions
- ST-246 400 mg, ST-246 600 mg, Placebo
- Drug
- Lead sponsor
- SIGA Technologies
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- Santa Ana, California • Orlando, Florida • Honolulu, Hawaii